<DOC>
	<DOCNO>NCT01834014</DOCNO>
	<brief_summary>The correlation value angiogenesis-related growth factor plasma efficacy , biomarkers relevant prognostic factor predictive factor sensitivity resistance treatment examine exploratively .</brief_summary>
	<brief_title>Exploratory Study Achievement Improved Survival Molecular Targeted Chemotherapy Liver Resection Not Optimally Resectable Colorectal Liver Metastases</brief_title>
	<detailed_description>The correlation value angiogenesis-related growth factor plasma efficacy , biomarkers relevant prognostic factor predictive factor sensitivity resistance treatment examine exploratively .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Patients register ATOM trial sign informed consent prior initiation trialspecific procedure treatment .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Liver metastasis KRAS Exon 2 wild type</keyword>
	<keyword>Liver metastasis RAS wild type</keyword>
</DOC>